Tonix Pharmaceuticals Holding (Nasdaq:TNXP) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

TNXP 주식 개요

바이오 제약 회사인 토닉스 파마슈티컬스 홀딩스는 인간의 질병을 치료 및 예방하고 고통을 완화하기 위한 치료제를 개발, 발견, 상용화 및 라이선싱하는 데 주력하고 있습니다.

TNXP 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

수익은 연간 50.08% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

의미 있는 시가총액이 없습니다. ( $5M )

최근 3개월간 주가 변동폭 심해

지난 1년 동안 주주가 크게 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Tonix Pharmaceuticals Holding Corp. 경쟁사

Gamida Cell

OTCPK:GMDA.Q

US$2.6m

ASLAN Pharmaceuticals

NasdaqCM:ASLN

US$7.2m

Dominari Holdings

NasdaqCM:DOMH

US$11.9m

Sunshine Biopharma

NasdaqCM:SBFM

US$6.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Tonix Pharmaceuticals Holding
과거 주가
현재 주가	US$1.19
52주 최고치	US$60.16
52주 최저치	US$1.08
베타	2.17
11개월 변경	-78.81%
3개월 변경 사항	-88.90%
1년 변경 사항	-97.40%
33년 변화	-99.98%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	TNXP	US Biotechs	US 마켓
7D	6.3%	0.06%	0.1%
1Y	-97.4%	9.9%	24.1%

수익률 대 산업: TNXP 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: TNXP 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is TNXP's price volatile compared to industry and market?
TNXP volatility
TNXP Average Weekly Movement	23.7%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

안정적인 주가: TNXP 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: TNXP 의 주간 변동성은 지난 1년 동안 17% 에서 23% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2007	103	Seth Lederman	www.tonixpharma.com

바이오 제약 회사인 토닉스 파마슈티컬스 홀딩스는 인간의 질병을 치료 및 예방하고 고통을 완화하기 위한 치료제를 개발, 발견, 상용화 및 라이선싱하는 데 주력하고 있습니다. 젬브레이스는 성인 편두통 치료를 위한 젬브레이스 심터치와 토심라를 판매하고 있습니다. 중추신경계 질환과 희귀질환, 면역학 및 전염병 제품 후보에 초점을 맞춘 포트폴리오를 보유하고 있습니다.

Tonix Pharmaceuticals Holding Corp. 기본 사항 요약

Tonix Pharmaceuticals Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요?
TNXP 기본 통계
시가총액	US$5.44m
수익(TTM)	-US$98.59m
수익(TTM)	US$10.25m

0.5x

P/S 비율

-0.1x

P/E 비율

TNXP 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
TNXP 손익 계산서(TTM)
수익	US$10.25m
수익 비용	US$6.40m
총 이익	US$3.85m
기타 비용	US$102.44m
수익	-US$98.59m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-23.56
총 마진	37.55%
순이익 마진	-961.87%
부채/자본 비율	8.3%

TNXP 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

TNXP 주식 개요

보상

위험 분석

Tonix Pharmaceuticals Holding Corp. 경쟁사

OTCPK:GMDA.Q

US$2.6m

NasdaqCM:ASLN

US$7.2m

NasdaqCM:DOMH

US$11.9m

NasdaqCM:SBFM

US$6.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million.

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500

ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Recent updates

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million.

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500

ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting

Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers

Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700

Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers

Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder

Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023

Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) and Tonix Medicines, Inc. entered into an agreement to acquire Certain Assets of Upsher Smith Laboratories, LLC for $25 million.

Tonix Pharmaceuticals Holding Corp. Announces Publication of Results from Phase 3 RELIEF Trial of TNX 102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models At the 2023 American Transplant Congress

Tonix Pharmaceuticals Holding Corp. Announces the Presentation of Data Detailing the Mechanism of Action and Pharmacokinetics of TNX-601 ER

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. Announces the Discovery Byscientists of the Isomers of Racemic Tianeptine

Tonix Pharmaceuticals Holding Corp. Announces Molecular Mechanism of Action of Tianeptine, the Active Ingredient of the Company's TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) Product Candidate

Tonix Pharmaceuticals Holding Corp. Announces U.S. Food and Drug Administration Cleared the Investigational New Drug Application to Support A Phase 1 Clinical Trial with TNX-1500

Tonix Pharmaceuticals Holding Corp. Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

Tonix Pharmaceuticals Holding Corp. Announces Publication of Paper in Viruses Highlighting the Company’S Development of A Vaccine to Protect Against Monkeypox and Smallpox (Tnx-801)

Tonix Pharmaceuticals Holding Corp. Initiates Enrollment in Phase 2 ‘PREVENTION’ Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) entered into an agreement to acquire All of the assets of Healion Bio, Inc.

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $12.5 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs

Tonix Pharmaceuticals Achieves Enrollment of First 50% of Participants in the RESILIENT Study

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized Anti-Sars-Cov-2 Monoclonal Antibodies from Curia Global, Inc

Tonix Pharmaceuticals Holding Receives Letter from the Listing Qualifications Staff of the Nasdaq

Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $14.25 million in funding

Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder

Tonix stock rises on FDA nod to start trial of TNX-601 for depression

Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)

Tonix Pharmaceuticals Holding Corp Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID